GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DMS Imaging SA (XBRU:ALIMG) » Definitions » ROE %

DMS Imaging (XBRU:ALIMG) ROE % : -26.98% (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is DMS Imaging ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. DMS Imaging's annualized net income for the quarter that ended in Dec. 2023 was €-2.87 Mil. DMS Imaging's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was €10.63 Mil. Therefore, DMS Imaging's annualized ROE % for the quarter that ended in Dec. 2023 was -26.98%.

The historical rank and industry rank for DMS Imaging's ROE % or its related term are showing as below:

XBRU:ALIMG' s ROE % Range Over the Past 10 Years
Min: -1366.74   Med: -167.27   Max: -6.67
Current: -6.67

During the past 12 years, DMS Imaging's highest ROE % was -6.67%. The lowest was -1,366.74%. And the median was -167.27%.

XBRU:ALIMG's ROE % is ranked better than
76.58% of 1358 companies
in the Biotechnology industry
Industry Median: -43.445 vs XBRU:ALIMG: -6.67

DMS Imaging ROE % Historical Data

The historical data trend for DMS Imaging's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DMS Imaging ROE % Chart

DMS Imaging Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,366.74 - -9.17 -51.81 -6.91

DMS Imaging Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.85 -69.46 -27.46 13.18 -26.98

Competitive Comparison of DMS Imaging's ROE %

For the Biotechnology subindustry, DMS Imaging's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DMS Imaging's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DMS Imaging's ROE % distribution charts can be found below:

* The bar in red indicates where DMS Imaging's ROE % falls into.



DMS Imaging ROE % Calculation

DMS Imaging's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-0.709/( (10.64+9.892)/ 2 )
=-0.709/10.266
=-6.91 %

DMS Imaging's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Jun. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-2.868/( (11.365+9.892)/ 2 )
=-2.868/10.6285
=-26.98 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


DMS Imaging  (XBRU:ALIMG) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-2.868/10.6285
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-2.868 / 39.496)*(39.496 / 43.1465)*(43.1465 / 10.6285)
=Net Margin %*Asset Turnover*Equity Multiplier
=-7.26 %*0.9154*4.0595
=ROA %*Equity Multiplier
=-6.65 %*4.0595
=-26.98 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-2.868/10.6285
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-2.868 / -2.87) * (-2.87 / -1.758) * (-1.758 / 39.496) * (39.496 / 43.1465) * (43.1465 / 10.6285)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9993 * 1.6325 * -4.45 % * 0.9154 * 4.0595
=-26.98 %

Note: The net income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


DMS Imaging ROE % Related Terms

Thank you for viewing the detailed overview of DMS Imaging's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


DMS Imaging (XBRU:ALIMG) Business Description

Traded in Other Exchanges
Address
7 Rue des Chasseurs Ardennais, Liege, BEL, 4031
DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.

DMS Imaging (XBRU:ALIMG) Headlines

No Headlines